Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

ERBB4 confers metastatic capacity in Ewing sarcoma.

Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, da Cunha IW, Rodriguez-Viciana P, Cheng H, Tavares Guerreiro Fregnani JH, Reynolds P, Arceci RJ, Nicholson A, Triche TJ, Soares FA, Flanagan AM, Wang YZ, Strauss SJ, Sorensen PH.

EMBO Mol Med. 2013 Jul;5(7):1087-102. doi: 10.1002/emmm.201202343. Epub 2013 May 16.

2.

E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.

Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH.

Cancer Res. 2007 Apr 1;67(7):3094-105.

3.

miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.

Satterfield L, Shuck R, Kurenbekova L, Allen-Rhoades W, Edwards D, Huang S, Rajapakshe K, Coarfa C, Donehower LA, Yustein JT.

Int J Cancer. 2017 Nov 15;141(10):2062-2075. doi: 10.1002/ijc.30909. Epub 2017 Aug 8.

PMID:
28748534
4.

MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.

Li J, You T, Jing J.

Cell Prolif. 2014 Apr;47(2):152-60. doi: 10.1111/cpr.12093. Epub 2014 Feb 12.

PMID:
24517182
5.

Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.

Ren C, Ren T, Yang K, Wang S, Bao X, Zhang F, Guo W.

J Exp Clin Cancer Res. 2016 Mar 11;35:44. doi: 10.1186/s13046-016-0321-3.

6.

Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma.

Krook MA, Nicholls LA, Scannell CA, Chugh R, Thomas DG, Lawlor ER.

Mol Cancer Res. 2014 Jun;12(6):953-64. doi: 10.1158/1541-7786.MCR-13-0668. Epub 2014 Mar 20.

7.

Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.

Potratz J, Tillmanns A, Berning P, Korsching E, Schaefer C, Lechtape B, Schleithoff C, Unland R, Schäfer KL, Müller-Tidow C, Jürgens H, Dirksen U.

Mol Oncol. 2016 May;10(5):677-92. doi: 10.1016/j.molonc.2015.12.009. Epub 2015 Dec 20.

8.

hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells.

Passacantilli I, Frisone P, De Paola E, Fidaleo M, Paronetto MP.

Nucleic Acids Res. 2017 Dec 1;45(21):12270-12284. doi: 10.1093/nar/gkx831.

9.

Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway.

Kamura S, Matsumoto Y, Fukushi JI, Fujiwara T, Iida K, Okada Y, Iwamoto Y.

Br J Cancer. 2010 Jul 27;103(3):370-81. doi: 10.1038/sj.bjc.6605775. Epub 2010 Jul 6.

10.

High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases.

Hong SH, Tilan JU, Galli S, Izycka-Swieszewska E, Polk T, Horton M, Mahajan A, Christian D, Jenkins S, Acree R, Connors K, Ledo P, Lu C, Lee YC, Rodriguez O, Toretsky JA, Albanese C, Kitlinska J.

Oncotarget. 2015 Mar 30;6(9):7151-65.

11.

miR-124 represses the mesenchymal features and suppresses metastasis in Ewing sarcoma.

Li Y, Shao G, Zhang M, Zhu F, Zhao B, He C, Zhang Z.

Oncotarget. 2017 Feb 7;8(6):10274-10286. doi: 10.18632/oncotarget.14394.

12.

Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.

Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH.

Oncotarget. 2016 Jan 12;7(2):1451-63. doi: 10.18632/oncotarget.6385.

13.

PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death.

Hotfilder M, Sondermann P, Senss A, van Valen F, Jürgens H, Vormoor J.

Br J Cancer. 2005 Feb 28;92(4):705-10.

14.

Reactivation of TWIST1 contributes to Ewing sarcoma metastasis.

Choo S, Wang P, Newbury R, Roberts W, Yang J.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26721. Epub 2017 Sep 5.

PMID:
28873262
15.

IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells.

Lissat A, Joerschke M, Shinde DA, Braunschweig T, Meier A, Makowska A, Bortnick R, Henneke P, Herget G, Gorr TA, Kontny U.

BMC Cancer. 2015 Jul 28;15:552. doi: 10.1186/s12885-015-1564-7.

16.

G-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1.

Richter GH, Fasan A, Hauer K, Grunewald TG, Berns C, Rössler S, Naumann I, Staege MS, Fulda S, Esposito I, Burdach S.

J Pathol. 2013 May;230(1):70-81. doi: 10.1002/path.4170. Epub 2013 Mar 14.

PMID:
23338946
17.

PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.

Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK.

Oncotarget. 2015 Oct 6;6(30):28895-910. doi: 10.18632/oncotarget.5000.

18.

Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.

Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, Pötschger U, Kontny U, Kovar H.

Oncogene. 2014 Jul 24;33(30):3927-38. doi: 10.1038/onc.2013.361. Epub 2013 Sep 2.

19.

Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression.

Jin Z, Zhao C, Han X, Han Y.

BMC Cancer. 2012 Oct 18;12:480. doi: 10.1186/1471-2407-12-480.

20.

Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.

Niemeyer BF, Parrish JK, Spoelstra NS, Joyal T, Richer JK, Jedlicka P.

PLoS One. 2015 Jan 20;10(1):e0116895. doi: 10.1371/journal.pone.0116895. eCollection 2015. Erratum in: PLoS One. 2015;10(3):e0120830.

Supplemental Content

Support Center